The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCirata Regulatory News (CRTA)

Share Price Information for Cirata (CRTA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 57.50
Bid: 57.50
Ask: 58.00
Change: 5.00 (9.52%)
Spread: 0.50 (0.87%)
Open: 52.90
High: 58.00
Low: 52.00
Prev. Close: 52.50
CRTA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Q1 FY24 Trading Update

9 Apr 2024 07:00

RNS Number : 7644J
Cirata PLC
09 April 2024
 

9 April 2024

 

Cirata plc

("Cirata" or the "Company")

Q1 FY24 Trading Update

 

GTM and sales organization embedded for growth

 

 

Cirata plc (LSE: CRTA), announces a trading update for the quarter period ended March 31, 2024.  An accompanying video presentation and discussion can be found on the Cirata Investor Relations webpage here.

 

Summary

· Bookings for the period of $0.7m

· Steady build in pipeline

· Sales and partner activity increased

· Fifteen contracts signed, improved mix to "new and growth"

· Important new business secured in re-invigorated DevOps offering

· New releases of Live Data Migrator (LDM) and major release of DevOps (ALM)

· Cash position at the end March was $13.3m

· Management reconfirms FY24 bookings guidance of $13-15m (81%-108% YoY growth)

 

Trading update

 

Bookings in Q1 FY24 were $0.7m (Q1 FY23: $2.1m, which benefitted from a large renewal), with DevOps/Application Lifecycle management ("DevOps") software accounting for 51% of bookings and Data Integration ("DI") software accounting for 49% of bookings.

 

In total, fifteen contracts were signed in the quarter, nine of which were new and growth[1] contracts. This included two new contracts in DevOps, secured with Onsemi and Marvell Technology. The new subscription contract with Onsemi in DevOps represents the first positive step in the reboot of the DevOps business. New DI contracts included deals signed with the Bank of Nova Scotia, Westpac Banking Corp and a large African financial services group. We also saw further growth at Tesco, a returning customer. Two deals secured in Q1 were greater than $150K in value: one in DI and the other in DevOps. 

 

Technology is core to Cirata and its market differentiation. Further progress was made in Q1 on shaping the product roadmap with direct customer input for LDM. In DevOps, we announced the availability of Gerrit 3.7, and we are already in discussions with customers on Proof of Concept.

 

As previously outlined, deal slippage remained a feature of Q1 performance. Some of the orders that were targeted for FY23 Q4 closed in early FY24 and, similarly, some of the deals targeted for Q1 have also slipped with the expectation that these will now conclude in Q2. Issues contributing to slippage include the complex nature of enterprise sales for data integration, protracted procurement processes and the ramping of the new sales team. Establishing greater sales cycle predictability, therefore, remains a key priority for management, to move beyond the current non-linear growth trajectory. To that end, Q1 saw the final changes made to the company's Sales organization. With that complete, Management believes that the foundations are now, for the first time, in place to deliver steadily improving pipeline predictability and performance.

 

As previously reported, Management expects that bookings will be H2 weighted in FY24 as the pipeline builds and the Sales team becomes more proven. The FY24 bookings guidance, which Management reconfirms today, is based on an expectation of higher levels of sales activity, both direct and through partners, and on the current sales pipeline. The new GTM organization is bedding down and leads from partners and customer activity levels are increasing and contributing to pipeline growth.

 

A table of key performance indicators will be posted to the Investor Relations landing page Cirata KPI by 30 April 2024.

 

 

Stephen Kelly, Chief Executive Officer, commented.

 

"I want to provide a balanced scorecard and honest perspective on the progress of Cirata. We were disappointed by the actual Q1 bookings and again experienced deal slippage relating to the complex nature of enterprise sales, protracted procurement processes and the ongoing ramping of our new sales team. However, I am pleased with the increasing level of sales activity in the quarter, following the complete reboot of the GTM organization.

 

The cadence of customer interaction has ramped significantly, and we are seeing improved commercial re-engagement as evidenced by the range of logos we have contracted with in Q1. Signing our first new contract in DevOps for some years as well as securing new and returning logos in DI has been encouraging and energizing for our team. Innovation in both LDM and DevOps continues and provides differentiated and superior technology offerings for our customers.

 

As I said before, the recovery of Cirata, is likely to be non-linear but no-one should underestimate the focus we are placing on sharpening and improving our pipeline visibility and predictability. With the sales team now fully set, and with partner and customer interactions building, we remain focused on delivering against the guidance range and phasing we have set out for the year as a whole."

 

 

This announcement contains information that qualifies or may qualify as inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the company's obligations under Article 17 of MAR.

 

The person responsible for arranging the release of this announcement on behalf of Cirata plc is Larry Webster, Company Secretary. 

 

 

For further information, please contact: 

 

Cirata

Via FTI Consulting

Stephen Kelly, Chief Executive Officer

Ijoma Maluza, Chief Financial Officer

Daniel Hayes, Investor Relations

FTI Consulting

+44 (0)20 3727 1137

Matt Dixon /Kwaku Aning / Usama Ali

Stijfel (Nomad and Joint Broker)

+44 (0)20 7710 7600

Fred Walsh / Richard Short / Tom Marsh

Liberum (Joint Broker)

+44 (0)20 3100 2000

Max Jones / Edward Mansfield / John More

 

About Cirata

 

Cirata, accelerates data-driven revenue growth by automating data transfer and integration to modern cloud analytics and AI platforms without downtime or disruption. With Cirata, data leaders can leverage the power of AI and analytics across their entire enterprise data estate to freely choose analytics technologies, avoid vendor, platform, or cloud lock-in while making AI and analytics faster, cheaper, and more flexible. Cirata's portfolio of products and technology solutions make strategic adoption of modern data analytics efficient and automated. For more information about Cirata, visit www.cirata.com

 


[1] New & Growth refers to either a new contract or additional consumption on an existing contract.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSSIEFAELSELL
Date   Source Headline
14th May 20243:28 pmRNSResult of Annual General Meeting
29th Apr 20245:01 pmRNSFurther re: Annual Report & Notice of AGM
24th Apr 20247:00 amRNSDirectorate Change
17th Apr 20243:05 pmRNSAnnual Report & Notice of AGM
9th Apr 20247:00 amRNSQ1 FY24 Trading Update
4th Apr 20247:00 amRNSFinal Results
6th Mar 20245:19 pmRNSHolding(s) in Company
4th Mar 20242:53 pmRNSHolding(s) in Company
21st Feb 20241:27 pmRNSHolding(s) in Company
15th Feb 20244:27 pmRNSDirector/PDMR Shareholding
15th Feb 20247:00 amRNSChair appointment
9th Jan 20247:00 amRNSTrading Update
4th Jan 20243:10 pmRNSTotal Voting Rights
4th Jan 20242:41 pmRNSHolding(s) in Company
3rd Jan 20245:40 pmRNSHolding(s) in Company
2nd Jan 20249:32 amRNSNotice of Q4 FY23 Trading Update
14th Dec 20236:12 pmRNSBlock Listing Application
12th Dec 20235:32 pmRNSGrant of Share Options to PDMRs
12th Dec 20238:29 amRNSHolding(s) in Company
7th Dec 20237:00 amRNSDirector/PDMR Shareholding
6th Dec 20237:00 amRNSTotal Voting Rights
5th Dec 202310:25 amRNSHolding(s) in Company
24th Nov 20235:40 pmRNSDirector/PDMR Shareholding
23rd Nov 202310:08 amRNSHolding(s) in Company
21st Nov 20235:41 pmRNSHolding(s) in Company
21st Nov 20231:28 pmRNSHolding(s) in Company
21st Nov 20237:00 amRNSDirector/PDMR Shareholding
17th Nov 20235:54 pmRNSDirector/PDMR Shareholding
8th Nov 20231:18 pmRNSHolding(s) in Company
7th Nov 20232:39 pmRNSTotal Voting Rights
2nd Nov 20237:00 amRNSChange of Auditor
27th Oct 20235:12 pmRNSHolding(s) in Company
18th Oct 20237:00 amRNSTrading Update and Outlook
6th Oct 202312:12 pmRNSHCSC renews contract
6th Oct 202311:24 amRNSHolding(s) in Company
5th Oct 202310:39 amRNSNotice of Q3 FY23 Trading Update
5th Oct 20239:00 amRNSNatWest expands contract
5th Oct 20237:00 amRNSConfirmation of Ticker Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.